33.21
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN
What drives Avidity Biosciences Inc. stock priceOverwhelming profit margins - jammulinksnews.com
Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks
Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
Is Avidity Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha
RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat
Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada
Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com
Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener
(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):